EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSUPAG00010005082
Gene Symbol: HCN4
1 Cross references
287 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSUPAG00010019430
Gene Symbol: HCRTR1
1 Cross references
96 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSUPAG00010005715
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSUPAG00010002639
Gene Symbol: IDO1
3 Cross references
98 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSUPAG00010022720
Gene Symbol: IKBKB
1 Cross references
197 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSUPAG00010001856
Gene Symbol: IMPDH1
3 Cross references
333 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSUPAG00010022794
Gene Symbol: IMPDH2
3 Cross references
200 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSUPAG00010010491
Gene Symbol: INPP5D
3 Cross references
213 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSUPAG00010010504
Gene Symbol: IGF1R
1 Cross references
274 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSUPAG00010019031
Gene Symbol: INSR
1 Cross references
288 Possible Orthologues:

Integrin Subunit Alpha 2b

Ensembl ID : ENSUPAG00010001927
Gene Symbol: ITGA2B
3 Cross references
189 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSUPAG00010005643
Gene Symbol: ITGA4
1 Cross references
236 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).